Forcyte Biotechnologies, Inc. was formed to leverage FLECS Technology (originally developed in the Di Carlo Lab @ UCLA) to provide drug-makers and researchers direct access to cellular force generation at the single-cell level – a cellular behavior that was previously inaccessible in an automated way.
We provide a fundamentally new class of cell-based assays that functionally evaluate single-cell contractility, integrated into standard multi-wellplate vessels – available both as end-to-end services, and as consumables.
Precision-Cut Lung Slice / ex vivo model for lung fibrosis
We induce fibrotic activation and phenotypes in human PCLS using fibrotic growth factors and evaluate fibrotic gene expression using RT-qPCR to evaluate effects of test compounds.
Inquire for more details.
Functional single-cell contractility / contraction / traction force assay -- use proprietary single-cell assay modality to quantify contractile cell force in 100s of primary cells simultaneously using automation. Ref: https://www.nature.com/articles/s41551-018-0193-2
- Screen compound libraries for effects on mechanical contraction of cells (384 format / >5K cmpds per day)
- Dose-response testing (20 steps / 2 fold serial dilution)
- Synergy testing of compound combinations
-Respiratory / airway smooth muscle contraction
-Reproductive / uterine smooth muscle contraction
- CV / arterial smooth muscle contraction
- bladder / bladder smooth muscle contraction
- precision cut lung slice model of pulmonary fibrosis
We can perform HTS for effects on contractility in numerous primary cell types using our 200K compound library, or using your compounds
Forcyte Biotechnologies, Inc has not received any reviews.
Forcyte Biotechnologies, Inc has not received any endorsements.